manufacturing is the sole category represented across all 1 tracked stories. Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Theragenics
manufacturing is the sole category represented across all 1 tracked stories. Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window. Their average consequence score of 6 runs below the beat's 6.8 for that window. Theragenics appears in 1 tracked Supply Chain story from March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Theragenics. Shared-story counts are live from our verified record — not editorial picks.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.